NovoCare vs LillyDirect: the direct-pay showdown
The two cheapest brand channels in the market are the manufacturers' own pharmacies — but they sell different molecules with different pricing philosophies, different traps, and very different fulfillment reputations. The honest comparison.
First, the thing that decides it for most people#
These programs don't sell the same drug. NovoCare is semaglutide (Wegovy, pen and pill; Ozempic for diabetes). LillyDirect is tirzepatide (Zepbound) and now orforglipron (Foundayo). If you and your prescriber have already settled on a molecule, the "choice" is made — this comparison matters most if you're genuinely open to either, or choosing which pill to start with.
And both share the same structural catch: they fill prescriptions, they don't write them. You bring your own prescriber, or add a one-off telehealth visit — the play our insurance guide and Sesame dossier cover.
Pricing philosophy: flat vs ladder#
| NovoCare (Wegovy) | LillyDirect (Zepbound) | |
|---|---|---|
| Injectable | $349/mo flat, all standard doses (7.2 mg high-dose: $399) | $299 (2.5 mg) → $399 (5 mg) → $449 (7.5–15 mg) |
| Pill | Wegovy pill: $149 / $199 / $299 by dose | Foundayo: $149 → $349 by dose (promo tiers through 2026) |
| Intro offer | $199/mo for the first two fills (starter pen doses, new patients, through 12/31/26) | $299 at the 2.5 mg entry dose |
| The catch | Consult not included — bring a prescription | Maintenance pricing requires refilling within 45 days; lapse and 10–15 mg pens revert toward $699. Max 11 fills/yr |
The philosophies differ genuinely: Novo priced the pen flat — your cost doesn't climb as you titrate up. Lilly priced a ladder — cheaper to start, more expensive to maintain at higher doses, with a punctuality requirement attached. Over a year at full maintenance dose, that's roughly $4,188 at NovoCare's flat pen versus $5,388 at LillyDirect's top tiers — if you never miss the 45-day window.
The fulfillment reputations are not symmetrical#
Our trust file gives NovoCare no channel-level review base yet (it launched March 2025 and has no standalone Trustpilot profile). LillyDirect has one, and it's rough: 1.6/5 across 94 reviews, an unclaimed profile where 82% of reviews are one-star — overwhelmingly fulfillment and logistics complaints, not pricing ones. Small sample, worth exactly what a small sample is worth — but it's the reason our LillyDirect dossier carries a flag and says "budget patience."
The Medicare wrinkle#
If you're on Part D, the $50/month Bridge copay covers Wegovy pens and pills, Foundayo, and the Zepbound KwikPen only — not the single-dose vials. Bridge-eligible patients shouldn't be paying either cash price at all.
The verdict, by situation#
- Prioritizing lowest entry price on a pill: tie at $149 — Wegovy pill 1.5 mg vs Foundayo 0.8 mg (promo). Different molecules; your prescriber's call, not a pricing site's.
- Planning for high-dose maintenance on an injectable: NovoCare's flat $349 beats LillyDirect's $449-with-conditions.
- Starting low and unsure you'll continue: LillyDirect's $299 entry is the cheapest brand injectable first month ($199 NovoCare intro aside).
- Bad at calendar discipline: NovoCare — the 45-day trap is real money.
- On tirzepatide specifically: there's no contest to have; LillyDirect is the direct channel, and its dossier's advice stands: set the refill reminder the day the box arrives.
Prices as listed on the dates shown on our index; both programs' terms change — checkout is the final word. Which molecule fits you is a clinician conversation, not ours. Neither manufacturer pays us anything — disclosure.